engleski

Cytotoxic Activity of Novel Palladium-Based Compounds on Leukemia Cell Lines

Effective treatments for human leukemias are in development, but so far none of them is completely satisfying. It was recently reported that palladium complexes have a significant anti-cancer activity as well as lower toxicity compared to some clinically used chemotherapeutics. Anti-cancer activities of two novel palladium (II) complexes [Pd(sac)(terpy)](sac)·4H2O and [PdCl(terpy)](sac)·2H2O were tested against three human leukemia cell lines, Jurkat, MOLT-4 and THP-1, in comparison to cisplatin and adriamycin. Cytotoxic effect of drugs was determined with the MTT assay. Cell death was assessed with FITC-Annexin/PI staining for flow cytometry. Furthermore, p53 phosphorylation, PARP cleavage and Bax and Bcl-2 mRNA levels were examined to elucidate mechanisam of cell death induction. Both complexes exhibited a significant dose-dependent antigrowth effect in vitro. The complexes predominately induced apoptosis, but necrosis was also observed. In vitro results have shown that palladium (II) complexes may be regarded as potential anti-cancer agents for treating human leukemia. Therefore, further analysis to determine putative mechanism of action and in vivo studies on animal models are warranted.

leukemia; palladium (II) complexes; apoptosis; PARP; cytotoxicity

nije evidentirano